Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cardiff Oncology, Inc. (CRDF)
NASDAQ:CRDF
Holding CRDF?
Track your performance easily
CRDF Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.15 - $6.42
Previous Close$2.45
Volume483.57K
Average Volume (3M)702.99K
Market Cap
$125.28M
Enterprise Value$69.30M
Total Cash (Recent Filing)$57.67M
Total Debt (Recent Filing)$1.69M
Price to Earnings (P/E)―
Beta1.66
Next Earnings
Feb 27, 2025EPS Estimate
-$0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.95
Shares Outstanding51,133,747
10 Day Avg. Volume1,184,145
30 Day Avg. Volume702,990
Standard Deviation0.41
R-Squared0.06
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)2.69
Price to Sales (P/S)194.44
Price to Cash Flow (P/CF)-3.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue100.58
Enterprise Value/Gross Profit142.00
Enterprise Value/Ebitda-1.56
Forecast
1Y Price Target
$10.50Price Target Upside328.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Cardiff Oncology News
PremiumCompany Announcements
Cardiff Oncology Reports Positive Q3 2024 Results and Clinical Progress
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe CRDF-005 trial may position onvansertib for accelerated approval based on an ORR interim analysis, with PFS and OS being the endpoints for full approval.
Financial StabilityCardiff's financial resources are sufficient to provide an operational runway through 3Q25, well beyond the data readout from the CRDF-004 trial.
Partnership And CollaborationDespite potential changes in Pfizer's portfolio, Cardiff management has not observed any decline in enthusiasm from Pfizer regarding their collaboration.
Bears Say
Clinical ResultsNegative or poorer-than-anticipated clinical results for onvansertib in the ongoing CRDF-004 trial.
Clinical Study DelaysDelays in advancing onvansertib into pivotal clinical studies.
Regulatory ApprovalFailure to obtain onvansertib approval.
---
Ownership Overview
6.06% Insiders
6.15% Mutual Funds
2.67% Other Institutional Investors
77.59% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CRDF FAQ
What was Cardiff Oncology, Inc.’s price range in the past 12 months?
Cardiff Oncology, Inc. lowest stock price was $1.15 and its highest was $6.42 in the past 12 months.
What is Cardiff Oncology, Inc.’s market cap?
Currently, no data Available
When is Cardiff Oncology, Inc.’s upcoming earnings report date?
Cardiff Oncology, Inc.’s upcoming earnings report date is Feb 27, 2025 which is in 95 days.
How were Cardiff Oncology, Inc.’s earnings last quarter?
Cardiff Oncology, Inc. released its earnings results on Nov 07, 2024. The company reported -$0.25 earnings per share for the quarter, beating the consensus estimate of -$0.269 by $0.019.
Is Cardiff Oncology, Inc. overvalued?
According to Wall Street analysts Cardiff Oncology, Inc.’s price is currently Undervalued.
Does Cardiff Oncology, Inc. pay dividends?
Cardiff Oncology, Inc. does not currently pay dividends.
What is Cardiff Oncology, Inc.’s EPS estimate?
Cardiff Oncology, Inc.’s EPS estimate is -$0.25.
How many shares outstanding does Cardiff Oncology, Inc. have?
Cardiff Oncology, Inc. has 51,133,747 shares outstanding.
What happened to Cardiff Oncology, Inc.’s price movement after its last earnings report?
Cardiff Oncology, Inc. reported an EPS of -$0.25 in its last earnings report, beating expectations of -$0.269. Following the earnings report the stock price went down -24.694%.
Which hedge fund is a major shareholder of Cardiff Oncology, Inc.?
Among the largest hedge funds holding Cardiff Oncology, Inc.’s share is Elkhorn Partners Limited Partnership. It holds Cardiff Oncology, Inc.’s shares valued at 120K.
---
Cardiff Oncology Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.50 (328.57% Upside)
$10.50 (328.57% Upside)
Blogger Sentiment
Bullish
CRDF Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 51.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.1%
Last 30 Days ▲ 14.5%
Last 30 Days ▲ 14.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
105.88%
12-Months-Change
Fundamentals
Return on Equity
-67.57%
Trailing 12-Months
Asset Growth
-28.89%
Trailing 12-Months
Company Description
Cardiff Oncology, Inc.
Trovagene, Inc. is a clinical-stage, precision cancer medicine oncology therapeutics company, which engages in the development of drugs that target cell division (mitosis), for the treatment of various cancers including leukemia, lymphomas, and solid tumors. The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan on August 4, 1999 and is headquartered in San Diego, CA.
---
CRDF Earnings Call
Q2 2024
0:00 / 0:00
---
CRDF Stock 12 Month Forecast
Average Price Target
$10.50
▲(328.57% Upside)
Technical Analysis
Best Analysts Covering CRDF
1 Year
1 Year Success Rate
5/9 ratings generated profit
1 Year Average Return
+50.39%
reiterated a buy rating 16 days ago
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 55.56% of your transactions generating a profit, with an average return of +50.39% per trade.
---